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Abstract Some natural and glycon-modified dNTPs with P,y-
pyrophosphate substitution at the triphosphate residue were 
synthesized and studied to evaluate the effect of these modifica-
tions on substrate properties of dNTPs in DNA synthesis 
catalyzed by human placental DNA polymerases a and P, avian 
myeloblastosis virus reverse transcriptase, and calf thymus 
terminal deoxynucleotidyl transferase. Reverse transcriptase 
proved to be the enzyme least specific to such modifications; 
the substrate activity of P,y-methylenediphosphonate substituted 
dTTP and 3'-azido-3'-deoxy-dTTP decreased in the following 
order: CF2 = CHF > CBr2 > C F M e » C H 2 . This order is 
individual for each DNA polymerase. It is interesting to mention 
that P,Y-CBr2 substituted dTTP is neither a substrate nor an 
inhibitor of DNA polymerase p. This specificity distinguishes 
DNA polymerase P from other DNA polymerases studied. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
dNTP are known to be rapidly dephosphorylated in inter-
and intracellular media as well as during their diffusion into 
cells. This property limits their use in nucleic acids biosyn-
thesis studies. Design of dNTP analogs which are stable 
enough in the presence of dephosphorylating enzymes may 
involve either replacement of the triphosphate residue by an-
other group or protection of the triphosphate function by any 
chemical residue which is removed inside the cell. Recent 
studies have demonstrated that particular triphosphate mod-
ifications do not affect markedly the substrate properties of 
dNTP toward different DNA polymerases, but essentially in-
crease the stability of the triphosphate in the presence of de-
phosphorylating enzymes [1,2]. However, triphosphate modi-
fications for designing effective and selective substrates/ 
inhibitors of DNA polymerases remain to be suggested. Be-
sides, the dependence of substrate specificity of different DNA 
polymerases on the structure of modified triphosphate residue 
has received little study. 
We synthesized several modified dNTP of Ia-c, Ila-c, and 
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IIIa,b types (Fig. 1). As a nucleoside component we used 
either natural thymidine (as in I), or the well known inhibitor 
of HIV replication, 3-azido-3'-deoxythymidine (as in II). As a 
structural basis for III, (Z)-l-[4-(phosphonomethoxy)but-2-
enyl]thymine was used. Its P,y-diphosphate, as well as diphos-
phates of the corresponding nucleotides with other nucleic 
bases, selectively terminated DNA synthesis at the catalysis 
by retro viral reverse transcriptases [3]. 
Substrate properties of I III were evaluated in DNA syn-
thesis reactions catalyzed by AMV reverse transcriptase, 
DNA polymerases a and P from human placenta, and calf 
thymus TDT. The above mentioned DNA polymerases re-
vealed different selectivity towards dNTP with structurally 
similar substituents in the triphosphate residue. 
2. Materials and methods 
Thymidine 5'-monophosphate was from Sigma; AZT 5'-mono-
phosphate was obtained according to Ref. [4]. (Z)-l-[4-(phosphono-
methoxy)but-2-enyl]thymine was synthesized as described in Ref. [3]. 
Diphosphonic acids were prepared by dissolving the corresponding 
tetrakis(trimethylsilyl) diphosphonates [5] in aqueous pyridine fol-
lowed by column chromatography of the obtained emulsion on Dow-
ex 50W4 (H+) and concentration of the eluted fractions in vacuo. 
Compounds I—III were synthesized as in Ref. [2] and analyzed by 
HPLC. 31P NMR spectra with P-H decoupling were recorded at 
162 MHz, 85% H3P04 and D20 were used as an external standard 
and solvent, respectively; 19F NMR spectra were recorded on a 
Bruker AC 200F spectrometer at 188.3 MHz, CF3COOH served as 
an external standard. 
The yields and physicochemical parameters of the compounds pre-
pared are presented in Table 1. 
2.1. Enzymes and DNA 
All the enzymes and template-primer complex were obtained as in 
Ref. [1]. All experiments were carried out as in Ref. [1]. 
3. Results 
The compounds under study were examined using the tem-
plate-tetradecadeoxynucleotide primer complex (Fig. 2) in 
DNA synthesis catalyzed by AMV reverse transcriptase 
(Fig. 3A), human DNA polymerase P (Fig. 3B), human 
DNA polymerase oc (Fig. 3C), and calf thymus TDT (Fig. 
3D), but in TDT assays no template was used. The primer 
was selected so that the next nucleotide residue in the growing 
DNA chain would be thymidylic acid or its analog. 
It is evident from Fig. 3A that compounds of type I are 
substrates and of type II are terminating substrates for AMV 
reverse transcriptase. The most potent among the compounds 
of type I was la. It elongated primer with practically the same 
efficiency as dTTP (compare lanes 2 and 5 in Series E). The 
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Fig. 1. Structures of the compounds synthesized. 
GGGTCAGTGCTGCAACATTTTGCTGCCGGTCACGGTTCGAACCCGACGTCCAGCTGAGATCTCCTA. 
CCCAGTCACGACGT > 
Fig. 2. Structure of the template-primer complex. 
Table 1 
Yields and 31P and 19F NMR spectra data of I-III 
Compound 
la 
lb 
Ic 
Ha 
lib 
lie 
Ilia 
111b 
Yield 
11 
22 
35.5 
37 
17.6 
14 
21 
27 
(%) 31P NMR, 5, 
cc-P 
-10.2, d, (30.1) 
-10.3, d, (27.3) 
-10 .1 , (32.4) 
-10.4, (22.5) 
-10.45, d, (27.6) 
-10.24, d, (31.1) 
10.5, d, (30.1) 
9.69, d, (29.0) 
ppm (J, Hz) 
p-P 
- 3 . 1 , m 
2.64, m 
6.98, ddd 
-3.86, ddt 
2.89, ddd 
6.2, ddd 
8.16, d 
0.9, m 
(73.1, 30.3, 32.4) 
(31.2, 71.9, 28.1) 
(13.5) 
Y-P 
4.3, 
8.9, 
12.9, 
4.05, 
8.8, 
13.5, 
4.6, 
8.17, 
dt (66.0) 
dt (60.2) 
dt (68.9) 
dt (59.8, 79.9) 
dd (15.3, 60.9) 
dd 
dt (68.0) 
d (15.0) 
19F NMR, 8, ppm (J, Hz) 
-42 .1 , dd (80.0, 93.1) 
-141.2, ddd (61.0, 64.0, 45) 
-100.7, m 
incorporation of the nucleotide residue was slightly less for lb 
(lane 5, Series A) and up to one hundredfold weaker for Ic 
(intensity of the pentadecanucleotide band on lane 7, Series C, 
for Ic was similar to that on lane 5, Series E). The Michaelis 
constants and maximum reaction rates (Table 2) for one-step 
primer elongation by compounds I at the catalysis by AMV 
reverse transcriptase correlated with the incorporation pattern 
shown in Fig. 3A. After incorporation of the nucleotide res-
idue of Ia-c into the growing DNA chain, the synthesis con-
tinued efficiently if the incubation mixture contained dGTP 
(lanes 8, Series A, C, E, control lane 3), or dGTP+ 
dATP+dCTP (lanes 9, Series A, C, E, control lane 4). The 
presence of an extra band on lanes 3 and 8 is due to low 
fidelity of reverse transcriptase. Indeed, no extra band can 
be seen on the gels obtained for DNA polymerases a and (3 
(Fig. 3B and C). The pausing pattern on lane 9 (Series C), 
may be due to unspecific inhibitory effect of Ic. 
Among azides II, Ha was the most powerful terminating 
substrate (lanes 10-12, Series F), lib demonstrated a 10-50-
fold lower activity (lanes 10-12, Series B), and lie (Series D) 
was the least active. The Michaelis constant values for Ila-c 
correlated mainly with the pattern activities data presented in 
Fig. 3A. 
Fig. 3B demonstrates that lb is incorporated in DNA chain 
at the catalysis by DNA polymerase p with the efficiency close 
to that for dTTP; (compare lanes 7-9, Series A and lanes 2 -
4). Compound la elongated the primer about 10 times less 
efficiently than dTTP, and Ic proved to be even a weaker 
substrate which is evident from comparison of lanes 7-9 (Ser-
ies C and B) with lanes 2-4). No activity was observed for Id 
(Series D). 
Moreover, no inhibition of DNA synthesis catalyzed by 
DNA polymerase p was observed in the experiments when 
Id was used as a competitive inhibitor against dTTP, at the 
Id/dTTP molar concentration ratio of up to 160 (data not 
shown). 
Fig. 3. Panel (A): Primer extension catalyzed by AMV reverse transcriptase. Lanes: 1, template-primer+enzyme; 2, as in lane 1 +2 uM dTTP; 
3, as in lane 1 +2 uM dTTP+2 uM dGTP; 4, as in lane 1 +2 uM dTTP+2 uM dGTP, 2 uM dATP and 2 uM dCTP. Series A: as in lane 1 
+2 uM lb (lane 5) +20 uM lb (lane 6) +200 uM lb (lane 7) as in lane 1 and +200 uM Ib+2 uM dGTP (lane 8) as in lane 1 and +200 u.M 
Ib+2 uM dGTP+2 uM dATP and 2 uM dCTP (lane 9). Series B: as in lane 1 +2 uM lib (lane 10) +20 uM lib (lane 11) and +200 uM lib 
(lane 12). Series C and E: as Series A, but with Ic and la, correspondingly; Series D and F: as Series B, but with lie and Ha, correspondingly. 
Panel (B): Primer extension catalyzed by DNA polymerase p\ Lanes: 1, template-primer+enzyme; 2-4 as in lane 1 +0.2 uJVI, 2 uM and 20 |j,M 
dTTP; 5 as in lane 1 +20 uM dTTP+20 uM dGTP; 6 as in lane 1 +20 uM dTTP+20 uM dGTP+20 uM dATP and 20 uM dCTP. Series A: 
as in lane 1 +0.2 uM lb (lane 7) +2 uM lb (lane 8) +20 uM lb (lane 9), 20 uM Ib+20 uM dGTP (lane 10), 20 uM Ib+20 uM dGTP+20 uM 
dATP and +20 uM dCTP (lane 11). Series B, C and D: as in A, but with Ic, la and Id, respectively. Panel (C): Primer extension catalyzed by 
DNA polymerase a. Lanes: 1, template-primer+enzyme; 2-3 as in lane 1 +2 |a,M or 10 uM dTTP; 4, as in lane 1 +10 uM dTTP+10 uM 
dGTP; 5 as in lane 1 +10 u.M dTTP+10 uM dGTP, 10 uM dATP and 10 uM dCTP. Series A: as in lane 1 +2 uM lb (lane 6) +20 irM lb 
(lane 7) +200 uM lb (lane 8) +200 uM Ib+10 uM dGTP (lane 9) and +200 uM Ib+10 uM dGTP+10 uM dATP and 10 uM dCTP (lane 10). 
Series B and C: as in Series A, but with Ic and la, correspondingly. Series D: as in lane 1 +20 uM Id (lane 6) +200 uM Id lane 7) +800 uM 
Id (lane 8) +800 uM Id+10 uM dGTP (lane 9) +800 uM Id+10 uM dGTP+10 uM dATP+10 uM dCTP (lane 10). Panel (D): Primer extension 
catalyzed by TDT. Lane 1, template-primer+enzyme; lane 2 as in lane 1 +10 u.M dTTP; lane 3 as in lane 1 +10 uM AZTTP. Series A: as in 
lane 1 +1 (J.M lb (lane 4) +10 u.M lb (lane 5) +100 |xM lb (lane 6). Series B-D: as Series A, but with Ic, la and Id, respectively. 
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Table 2 
Kinetic parameters for I and II in one-step elongation reaction cata-
lyzed by AMV reverse transcriptase 
Compound 
la 
I, X = CH2 
lb 
Ic 
Id 
dTTP 
Ila 
lib 
lie 
AZTTP 
ATm (uM) 
1.25+0.17 
700a 
1.30+0.12 
11.38+2.27 
2.61+0.24 
1.02+0.01 
0.98+0.09 
10.34+1.68 
12.31+1.34 
0.76+0.02 
V IV dTTP 
' max' ' max w i l l 
0.81 
0.98 
1.15 
0.51 
1 
0.52 
0.82 
1.42 
0.68 
"According to Ref. [7]. 
Among the azido derivatives Ila-c, DNA polymerase (3 in-
corporated only lib at a low efficiency (data not shown). 
Triphosphates Ia-d were recognized by DNA polymerase a 
(Fig. 3C). The activity of the compounds la and lb was ap-
proximately the same and was more than 50-fold lower than 
that for dTTP (compare lanes 6-8, Series C and A, with lanes 
2-3); the activity of Ic (lanes 6-8, Series B) was even lower, 
and Id was incorporated in the DNA chain only at the con-
centration of 200 |J.M (lanes 6-8, Series D). After incorpora-
tion of la-Id, the DNA chain was further extended if the 
incubation mixture contained dGTP (lanes 9, Series A-D, 
control lane 4), or dGTP+dATP+dCTP (lane 10, Series A -
D, control lane 5). Pauses on lane 10 (Series A-D) correspond 
to the position of thymidylic acid residues (positions 32, 40, 
41, 46, 52, 57, 59, and 66). This effect may be ascribed to the 
lower dissociation rate of halogenated methylenepyrophos-
phonates after la-Id incorporation and, as a result, slower 
enzyme translocation along the template. This pattern is typ-
ical for DNA polymerase a due to its high polymerization 
activity (as compared with DNA polymerase (3) and high fidel-
ity (as compared with reverse transcriptase). 
Fig. 3D illustrates tetradecanucleotide elongation by the 
synthesized compounds in the presence of TDT. It can be 
seen that all I were good substrates for this enzyme, Ic being 
slightly less efficient. 
Compounds III were not substrates for HIV and AMV 
reverse transcriptases (data not shown). 
4. Discussion 
The results of our study demonstrate that replacement of 
the p,y-pyrophosphate residue in dTTP and, to some extent in 
AZTTP, by substituted p,y-methylenediphosphonate units 
maintains, as a rule, their substrate properties towards several 
DNA polymerases. Some dNTPS modified at the P,y-pyro-
phosphate residue have earlier been studied. P,y-Dibromome-
thylenediphosphonate and carboxyphosphonate analogs of 
dTTP were shown to be substrates for HIV, AMV, and 
RSV reverse transcriptases [6,7]; dTTP carboxyphosphonate 
analog was also a substrate for rat liver DNA polymerase P 
and calf thymus TDT, but was not utilized by calf thymus 
DNA polymerase a and E. coli DNA polymerase I [7]. Sugar-
modified dTTP bearing a P,y-methylenediphosphonate residue 
instead of the p,y-pyrophosphate also revealed substrate prop-
erties towards HIV reverse transcriptase and TDT [8], though 
its substrate activity was rather low. Guanine-related homolog 
of la was a substrate for B. subtilis DNA polymerase III, but 
was not recognized by E. coli DNA polymerase I [9]. 
Our data on the substrate properties of various modified 
dNTPs allowed us to formulate some principles concerning 
the specificity of different DNA polymerases. 
All the compounds of type I were shown to be good sub-
strates for AMV reverse transcriptase. Compounds Ila, lib 
and lid were efficiently utilized by AMV reverse transcriptase, 
but lie was a significantly less active substrate. TDT efficiently 
utilized la-Id as substrates, while DNA polymerase oc recog-
nized la and lb better than Ic; triphosphate Id proved to be 
the least active substrate. For DNA polymerase P, lb revealed 
the most potent substrate properties, la and Ic were slightly 
less active, and Id was not a substrate. Compounds III dem-
onstrated no substrate properties towards any DNA polymer-
ases. 
Thus, substrate properties of I and II toward AMV reverse 
transcriptase decrease in the following order: CF2 = 
CHF > C B r 2 > CFMe » C H 2 . For TDT, they may be ar-
ranged as follows: CF2 = CBr2 = CHF>CFMe. For DNA 
polymerase a, the relationship is different: CF2 = CHF > 
CFMe»CBr 2 . For DNA polymerase P, substrate activity 
of Ia-Ic decreased in the following order: C H F > C F 2 > 
CFMe; Id (X = CBr2) was neither a substrate nor an inhibitor 
of this enzyme. At the same time, DNA polymerase P incor-
porated lib, although azido-dNTPs are not substrates for this 
enzyme. 
The results obtained led us to the following conclusions. 
1. Modification of the triphosphate residue in dNTP, partic-
ularly of the P,y-pyrophosphate, allows one to modulate 
their substrate activity and selectivity, as it has been shown 
for glycon-modified dNTPs. 
2. Possibilities for direct interpolation of the data on the ac-
tivity of P,y-modified dNTPs from one DNA polymerase 
to another one are limited, probably due to differences in 
the structure of triphosphate binding sites of DNA poly-
merase active centers. 
3. The lack of specificity of DNA polymerase P towards Id 
was totally unpredictable, especially in view of the fact that 
this compound was a most potent substrate for AMV re-
verse transcriptase and TDT. It should be mentioned that 
DNA polymerase P did not utilize dTTP with bulky mod-
ifications at the y-phosphate residue [1]. It is possible that 
bulky groups at the y or P,y-phosphate prevent correct 
dNTP binding to the DNA polymerase P active center 
because of spatial hindrances. 
Thus, when designing dNTP analogs active and selective 
towards different DNA polymerases and stable in human 
blood, one should be aware of the fact that the substrate 
properties of these compounds differ for each enzyme and 
are defined by the particular combination of modifications 
in the dNTP molecule. 
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